Latest news with #Netherton
Yahoo
26-07-2025
- Yahoo
Car found with wheel hanging off and dodgy insurance - but that wasn't worst part
This was the aftermath of a crash in the Black Country which left a road blocked off. A single-vehicle collision involving a blue Skoda took place on Baptist End Road in the Netherton area of Dudley. The vehicle was left with one of its front wheels hanging off following the crash. READ MORE: Man with 'distinctive tattoos' sought after doorbell camera and car smashed up Get breaking news on BirminghamLive WhatsApp, click the link to join West Midlands Police officers discovered the car had a fraudulent insurance policy. But that wasn't the worst past - as a large knife was discovered inside the vehicle. The driver ran from the scene and enquiries were ongoing to trace him. The Skoda was seized as part of police enquiries. Taking to X, Brierley Hill Police wrote yesterday evening, July 25: "We have attended a single vehicle collision where the driver had ran off. "The car with a fraudulent insurance policy has been seized along with the large knife located inside. Man seriously injured after Handsworth stabbing as attackers still on run Police warning sent to protestors ahead of village's latest demonstration "Enquiries are on going to trace the driver."
Yahoo
26-07-2025
- Yahoo
Bid to trace driver after 'large knife' recovered from car crash
POLICE recovered a "large knife" from a car that crashed in Netherton. West Midlands Police posted an image on social media site X yesterday (July 25) of a blue Skoda that had crashed in Baptist End Road. Officers are currently still working to track down the driver who fled the scene. The car was found to have a fraudently insurance policy and was seized after the crash. In a statement, the force said: "We have attended a single vehicle collision where the driver had run off. "The car with a fraudulent insurance policy has been seized along with the large knife located inside. "Enquiries are ongoing to trace the driver."
Yahoo
25-07-2025
- Yahoo
Teenager arrested after police seize samurai sword from Dudley street
A teenager has been arrested after a samurai sword was seized by police in Dudley. Police were called to reports of a weapon being brandished in Netherton at around 4.35pm yesterday, July 23. A member of the public told officers they had seen a weapon on Wrens Nest Road. READ MORE: Woman fighting for her life after Selly Oak crash as hero locals rush to her aid A samurai sword was later recovered from the scene. Police then arrested a 15-year-old boy on suspicion of possession of a sharp pointed article in a public place. He remains in custody for questioning. A West Midlands Police spokesperson said: "A teenager has been arrested after we received reports of a weapon being brandished in Netherton. "Just after 4.35pm yesterday afternoon (23 Jul) we received a call from a member of the public after they had seen a weapon on Wrens Nest Road, Dudley. "We quickly responded and a 15-year-old boy was arrested on suspicion of possession of a sharp pointed article in a public place. He remains in custody for questioning. "A samurai sword was also recovered. "We take knife crime and carrying a weapon seriously. "If you know someone who is carrying a weapon please call us on 101 to report. "You can also talk to us online or report anonymously to Crimestoppers on 0800 555 111."
BBC News
03-07-2025
- BBC News
Attempted murder arrests over Netherton knife attack
Three men have been arrested on suspicion of attempted murder after a man was injured in a knife attack.A man in his 30s was taken to hospital after being slashed with a knife at a house in Netherton on Merseyside at about 01:00 BST, police said. He has since been discharged. The arrested men, aged 22, 34 and 37, all from Netherton, remain in custody for Insp Ted Barr urged witnesses or anyone with information or doorbell footage to get in touch. "This was clearly a serious assault on the victim," he said. "This could have been far worse and I want to reassure the community in Netherton that we are taking this extremely seriously." Listen to the best of BBC Radio Merseyside on Sounds and follow BBC Merseyside on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
Yahoo
10-06-2025
- Business
- Yahoo
Azitra, Inc. Announces Presentation at the 2025 BIO International Convention
BRANFORD, Conn., June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the company will present at the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome and ATR-04, in development for the treatment of moderate to severe EGFRi-associated dermal toxicity in adults. Details of the presentation are as follows: Event: 2025 BIO International Convention Date and Time: Tuesday, June 17 at 12:00 PM, ET Location: Boston Convention & Exhibition Center, Room 154 Presenter: Travis Whitfill PhD MPH, Cofounder and Chief Operating Officer During the conference, Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones. About Azitra, Inc. Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies. Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to present this abstract detailing the Phase 1/2 clinical trial or, if we are able to do so, that the abstract will be favorably received; we may experience delays in the dosing the first patient in this Phase 1/2 trial; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the SEC on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Norman StaskeyChief Financial Officerstaskey@ Investor Relations Tiberend Strategic Advisors, Nugent205-566-3026jnugent@ Media Relations Tiberend Strategic Advisors, McDonald646-577-8520cmcdonald@ View original content to download multimedia: SOURCE Azitra, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
